Program
zemprocitinib
Also written as “LNK01001”, “LNK01001 Dose A” and “LNK01001 Dose B”.
Its studies are mostly in Arthritis, Rheumatoid · Spondylitis, Ankylosing · Dermatitis, Atopic, led by Lynk Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lynk Pharmaceuticals | 61 open or running | phase 3since Feb 2, 2024 | Oct 10, 2023 | Nov 2026phase 3 · NCT07237568 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 10, 2023First studies: 3 phase 2 studiesFirst studyNCT06099535, NCT06085534, NCT06085521
- Feb 2, 20242 phase 3 studiesNCT06277245, NCT06276998
- Nov 16, 2025Phase 3 study in Spondylitis, AnkylosingNCT07237568 · 352 planned · China
Ahead
- Nov 2026Primary completion: phase 3 study in Spondylitis, AnkylosingNCT07237568
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07237568Spondylitis, Ankylosing · China | 3 | Recruiting | Nov 2026 | 352 |
| NCT06277245Dermatitis, Atopic · China | 3 | Completed | Apr 18, 2025 | 356 |
| NCT06276998Arthritis, Rheumatoid · China | 3 | Completed | Aug 22, 2025 | 430 |
| NCT06099535Arthritis, Rheumatoid · China | 2 | Completed | Dec 29, 2022 | 156 |
| NCT06085534Spondylitis, Ankylosing · China | 2 | Completed | Dec 6, 2022 | 177 |
| NCT06085521Dermatitis, Atopic · China | 2 | Completed | Jun 14, 2023 | 150 |
How it is read
Names in the registry
- “LNK01001”, 4 entries
- “LNK01001 Dose A”, 2 entries
- “LNK01001 Dose B”, 2 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 2 studies
- Spondylitis, Ankylosing, 2 studies
- Dermatitis, Atopic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.